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Abstract: Overactive bladder is a highly prevalent disorder with a significant impact on quality 
of life. Antimuscarinic agents are commonly used, but persistence is limited due to unsatisfactory 
efficacy and/or tolerability. Mirabegron is the first beta-3 adrenoceptor agonist approved for 
the treatment of overactive bladder syndrome. This paper reviews the pharmacology, mecha-
nism of action, efficacy, and safety of mirabegron. A PubMed search of all English articles 
 pertaining to mirabegron was performed. An alternative to antimuscarinics, mirabegron has a 
unique mechanism, improves overactive bladder symptoms and quality of life, and has limited 
adverse effects and few contraindications.
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Introduction
Overactive bladder (OAB) syndrome consisting of urgency, with or without urge 
incontinence, often with frequency and nocturia, is a highly prevalent disorder with 
a significant impact on quality of life. It is estimated that approximately 11%–15% 
of adults worldwide have OAB symptoms.1,2 The prevalence of OAB increases with 
age, affecting 30%–40% of the population .75 years of age.2,3 It is estimated that 
546 million individuals worldwide will be affected by OAB by 2018.4
OAB symptoms are the result of storage phase dysfunction. The etiology of OAB 
may be multifactorial, but at least two afferent signaling pathways have been defined,5 
ie, the myogenic and urothelial pathways.6,7 First-line treatment for OAB is behavioral 
therapy.8 Until recently, the only approved pharmacologic treatment for the management 
of OAB symptoms was antimuscarinic therapy. There are a variety of antimuscarinic 
agents available, which vary in their method of delivery, dose flexibility, molecular 
structure, muscarinic receptor affinity, and side effect profile. However, as a group, these 
agents are recognized to be safe and effective in the management of OAB symptoms.9–11 
Compliance with antimuscarinic therapy is limited, and efficacy, tolerability, and cost 
have been cited as contributors.12,13 Mirabegron, the first beta-3 adrenoceptor agonist 
approved for the treatment of OAB symptoms, provides an alternative to antimuscar-
inic therapy and has a unique mechanism of action and side effect profile. This paper 
reviews the pharmacology, mechanism of action, efficacy, and safety of mirabegron 
based on a PubMed search of all English articles on mirabegron.
Compound and mechanism of action
The chemical name for mirabegron is (R)-(2-(2-amino-1,3-thiazol-4-yl)-N-(4–2-(((2R)-
2-hydroxy-2-phenyethyl)amino)ethyl)phenyl)acetamide. Mirabegron is a potent and 
selective agonist for the human beta-3 adrenoceptor. A radioligand competition binding 
Research and Reports in Urology 2013:5submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
148
Lee et al
assay with mirabegron found a 1,000-fold higher affinity for 
the human beta-3 adrenoceptor over the human beta-1 adreno-
ceptor and beta-2 adrenoceptor. Mirabegron facilitates bladder 
filling and extends the storage phase by activating the beta-3 
adrenoceptor.14 In mammals, detrusor relaxation is primarily 
mediated by the cyclic adenosine monophosphate pathway, 
which is activated by binding of noradrenalin to the beta adre-
noceptor.11,15 Both animal and human bladders have beta-1, 
beta-2, and beta-3 adrenoceptors.11 In the human bladder, the 
beta-3 is the more common type of adrenoceptor, and appears 
to be the main one mediating human detrusor relaxation.16–18 
Animal studies have demonstrated dose-dependent detrusor 
relaxation with beta-3 adrenoceptor agonists during the stor-
age phase of the micturition cycle, as well as inhibition of 
neurogenic overactivity and experimentally induced OAB, and 
OAB associated with bladder outlet obstruction.19–22 Beta-3 
adrenoceptor agonists increase bladder capacity without 
affecting micturition pressure or residual urine volume.5,19 In 
rats with spinal cord transection, beta-3 adrenoceptors have 
been demonstrated to directly inhibit afferent nerve activity.5 
Andersson et al reviewed the published literature on beta 
adrenoceptors and concluded that stimulation of the beta-3 
adrenoceptor relaxes detrusor smooth muscle, decreases affer-
ent signaling from the bladder, improves bladder compliance 
on filling, and increases bladder capacity.23
Pharmacokinetics and metabolism
The available formulation of mirabegron is an oral controlled 
absorption system and its oral bioavailability ranges from 
24% to 53%.24 There is substantial interindividual variability 
in the oral bioavailability of mirabegron, which is dependent 
on sex and dose. Sex differences in the oral bioavailability 
of mirabegron were noted in a large single-dose, open-label, 
randomized, parallel-group, crossover study in 91 subjects 
that also included females.24 There was a 64% increase in the 
area under the curve (AUC) in female subjects after oral dos-
ing (25–100 mg) relative to male subjects. A dose-dependent 
increase in oral bioavailability of mirabegron was observed, 
from 24% at the 50 mg dose to 45% at the 150 mg dose.24 The 
increased bioavailability at higher oral doses may be related 
to the interaction of mirabegron with P-glycoprotein, which is 
known to act as an intestinal efflux transporter.25 It is postulated 
that the dose-dependent increase in oral bioavailability may be 
related to saturation of P-glycoprotein by increasing concentra-
tions of mirabegron in the gut from higher oral doses.25,26
Mirabegron is extensively metabolized by the liver into at 
least 10 metabolites, none of which appear to be active in the 
treatment of OAB.27 The terminal elimination half-life ranges 
from 26 to 65 hours.28 Mirabegron undergoes several meta-
bolic pathways, including n-dealkylation, oxidative metabo-
lism mediated by cytochrome P450 (CYP)3A4/5,29 with a 
minor role of CYP2D6, amide hydrolysis by esterases, and 
glucuronidation mediated by uridine diphosphate glucurono-
syltransferases.26,27 The CYP2D6 gene is polymorphic and 
individuals may be stratified into ultrarapid metabolizers, 
extensive metabolizers, intermediate metabolizers, and poor 
metabolizers.30 Following a single oral dose of mirabegron 
(160 mg), the plasma exposure in poor metabolizers was 
19% higher than in extensive metabolizers.30 The amount of 
drug, as a percentage of the dose excreted in the urine was 
15.4% + 4.2% in poor metabolizers versus 11.7% + 3.0% in 
extensive metabolizers, which suggests that poor metabolism 
of mirabegron in poor metabolizers leads to slightly increased 
plasma exposure and urinary excretion of the drug.30
effect of food intake on pharmacokinetic 
properties of mirabegron
A single-dose, randomized, open-label, three-period, par-
allel-dose group, crossover study was performed in which 
a 50 mg or 100 mg mirabegron oral controlled absorption 
system was administered orally to healthy subjects in the 
fasted state or after a high-fat or low-fat breakfast. The 
primary endpoints for assessment of food effects were peak 
plasma concentration (C
max
) and area under the plasma con-
centration-time curve from time zero to infinity (AUC
0–inf
). 
With either the fed condition or dose, the 90% confidence 
intervals (CIs) for the fed/fasted ratios of both peak plasma 
concentration and AUC
0–inf
 for mirabegron fell below the 
predetermined range for bioequivalence (80%–115%), sug-
gesting that food had no effect on exposure to the mirabegron 
oral controlled absorption system. When mirabegron 50 mg 
or 100 mg was administered with a high-fat breakfast, the 
C
max
 decreased by about 39%–45%, and the overall exposure 
as measured by AUC
0–inf
 was decreased by about 17%–18%. 
A greater decrease was noted with a low-fat breakfast, where 
mirabegron C
max
 was decreased by about 64%–75% and the 
AUC
0–inf
 by about 47%–51%.31 The prescribing information 
from the US indicates that mirabegron can be taken with or 
without food at the approved doses.32
effect of renal impairment
An open-label, single-dose, parallel-group study evaluated 
the effect of renal impairment on mirabegron. This study 
included age-matched and weight-matched males and females 
with no impairment of renal function or mild, moderate, or 
severe impairment based on estimated glomerular filtration 
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rate. After a single oral dose of mirabegron 100 mg, the geo-
metric mean AUC
0–inf
 was 31%, 66%, and 118% higher in 
subjects with mild, moderate, and severe renal impairment, 
respectively. C
max
 increased by 6%, 23%, and 92% in mild, 
moderate, and severe renal impairment, respectively.25
effect of hepatic impairment
A study was performed to evaluate the impact of hepatic 
impairment on mirabegron. The Child-Pugh classifica-
tion for hepatic function was used to stratify both male 
and female subjects into healthy subjects with no hepatic 
impairment or those with mild or moderate impairment. 
Mild or moderate hepatic impairment was associated with 
an increase in C
max
 of 9% and 175%, respectively, com-
pared with healthy matched controls.25 The AUC
0–inf
 was 
increased by 19% and 65% in those with mild or moderate 
hepatic impairment, respectively, compared with healthy 
controls.25
effect of sex and age on pharmacokinetics 
of mirabegron
Two studies were performed to evaluate the effect of sex 
and age on the pharmacokinetics of mirabegron.28 The first 
study was a double-blind, randomized, placebo-controlled, 
multiple dose-escalation study using six separate dose levels, 
ie, 50 mg, 100 mg, 200 mg, and 300 mg of the mirabegron 
oral controlled absorption system for young subjects, and 
50 mg and 200 mg for elderly subjects. On day 1 of the 
study, 12 subjects received a single dose of mirabegron and 
four subjects received placebo, followed by a 3-day washout 
and once-daily dosing for 10 days at the selected dose level. 
The second study was an open-label crossover enrolling 
75 healthy subjects, comprising 36 healthy young (18 male 
and 18 female) and 39 older (21 male and 18 female) subjects 
stratified by age and sex and randomized to receive one of 
six treatment sequences, where each subject received two 
of three possible doses of the mirabegron oral controlled 
absorption system (25 mg, 50 mg, and 100 mg) in random 
sequence separated by a minimum of 14 days. Analysis of 
variance of AUC
0–inf
 and C
max
 following multiple doses of 
25–100 mg demonstrated no significant difference between 
older (.55 years) and younger subjects. However, analysis 
of variance identified a significant effect of sex on the phar-
macokinetics of mirabegron, with significantly higher C
max
 
and AUC
0–inf
 (38%–44%), respectively, in women of all age 
groups compared with men.28 The time taken to reach peak 
plasma concentration for mirabegron was independent of age 
in both single-dose and multiple-dose studies.26 The mean 
elimination half-life was overall slightly longer in the elderly 
as well as in women compared with men.
Drug-drug interactions
The ability of mirabegron to inhibit the activity of the most 
relevant CYP enzymes, including CYP1A1/2, 2B6, 2C8, 
2C9, 2C19, 2D6, 2E1, and 3A4/5, was studied in vitro using 
human liver microsomes.33 Except for CYP2D6, the in vitro 
concentration of mirabegron required for mediating the 50% 
inhibitory concentration (IC
50
) with and without preincubation 
amounted to .100 mmol/L,33 which is 370-fold higher than the 
C
max
 measured in human pharmacokinetic studies.24,28,34 Thus, 
mirabegron is not expected to have clinically significant drug-
drug interactions based on its therapeutic plasma exposure 
range of 79–630 ng ⋅ hour/mL and the high IC
50
 values needed 
for inhibition of CYP1A1/2, 2B6, 2C8, 2C9, 2C19, 2E1, and 
3A4/5.26 In addition to the potential effects of inhibition on 
CYP2D6, drug interactions may also be the result of the effect 
of other drugs on efflux transporters, such as P-glycoprotein,35 
that play a role in the bioavailability of mirabegron.24
Ketoconazole
A two-period, one-sequence, crossover study was performed 
evaluating the interaction of mirabegron with ketocon-
azole, a CYP3A4 and P-glycoprotein inhibitor, in a group 
of 24 healthy male (n=12) and female (n=12) adults.36 
Individuals received a single dose of mirabegron 100 mg on 
day 1 in period 1 and on day 4 in period 2, with multiple dosing 
of ketoconazole 400 mg once daily from day 1 to day 9. The 
steady-state plasma levels of ketoconazole caused a 1.4-fold 
and 1.8-fold increase in C
max
 and AUC
0–inf
, respectively.
Rifampin
The interaction of rifampin, a potent inducer of several CYP 
enzymes, including CYP3A, 2B6, 2C9, and 2C19 as well as 
a weak inducer of CYP1A2, uridine diphosphate glucurono-
syltransferase, and transporters including P-glycoprotein, with 
mirabegron was evaluated in a one-sequence, crossover study 
in 24 healthy adults, comprising 13 males and 11 females.36 
This 15-day study evaluated the effect of repeat doses of 
rifampin 600 mg per day given from day 5 for 10 days onwards 
on the pharmacokinetics of a single 100 mg dose of mirabe-
gron administered on day 1 and on day 12. Coadministration 
of rifampin resulted in a 0.35-fold and 0.44-fold decrease in 
the C
max
 and AUC
0–inf
 of mirabegron, which could be related 
to induction of P-glycoprotein in the intestine, resulting in 
reduced oral bioavailability, which is consistent with a lack of 
effect on the elimination half-life of mirabegron. The amount 
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of mirabegron as a percentage of the dose excreted in urine 
decreased from 7.8% to 4.5% in the presence of rifampin.36
Another study evaluated the effect of CYP2D6 inhibition 
by mirabegron. In this 38-day study, 28 healthy individuals 
received a single oral dose of 50 mg desipramine on days 1, 18, 
and 38 of the study. Mirabegron 100 mg was given daily from 
day 5 to day 23 to achieve steady-state levels. The result was an 
increase in the elimination half-life of desipramine and a 1.8-
fold and 3.4-fold increase in C
max
 and AUC
0–inf
, respectively.37
When mirabegron is used concomitantly with drugs 
that are metabolized by CYP2D6, especially those with a 
narrow therapeutic index (ie, thioridazine, flecainide, and 
propafenone), appropriate monitoring and possible dose 
adjustment of such drugs may be necessary.38
Digoxin
When given in combination with digoxin, mirabegron increased 
the mean C
max
 of digoxin from 1.01 ng/mL to 1.3 ng/mL 
(29%) and the AUC from 16.7 ng ⋅ hour/mL to 19.3 ng ⋅ hour/
mL (27%). Thus, it is recommended that the lowest dose for 
digoxin should initially be considered in patients who are start-
ing a combination of mirabegron and digoxin.38
warfarin
The mean C
max
 of S-warfarin and R-warfarin was increased by 
approximately 4% and the AUC by approximately 9% when 
warfarin was administered as a single dose of 25 mg after mul-
tiple doses of mirabegron 100 mg; however, there was no effect 
on the international normalized ratio (INR) or prothrombin 
time. The effect of mirabegron on multiple doses of warfarin 
and on warfarin pharmacodynamic endpoints such as INR and 
prothrombin time has not been fully investigated.38
Oral contraceptives
With multiple dosing of mirabegron 100 mg once daily, there 
were no changes in the plasma concentrations of combined 
oral contraceptives (ethinyl estradiol/levonorgestrel, both of 
which are CYP3A4 substrates).32
Metformin
Coadministration of metformin 500 mg twice daily with 
mirabegron immediate-release 160 mg once daily resulted in 
an approximately 20% decrease in the mean C
max
 and AUC of 
mirabegron.32 There was no relevant effect of multiple doses 
of mirabegron immediate-release on the AUC
0–inf
 and C
max
 of 
metformin.32
Combination therapy in OAB and benign  
prostatic hypertrophy
The effect of coadministration of solifenacin 10 mg and 
mirabegron 100 mg once daily was evaluated in healthy 
volunteers. The mean mirabegron C
max
 was not affected by 
concomitant solifenacin; however, the mean solifenacin C
max
 
and AUC
0–inf
 were increased by 23% and 26%, respectively, 
with concomitant mirabegron. Caution is recommended when 
combining mirabegron with an antimuscarinic agent to treat 
OAB because of the risk of urinary retention.38
The cardiovascular results of a study in healthy men 
45 years of age and older does not suggest a clinically rel-
evant pharmacodynamic interaction between tamsulosin and 
mirabegron.32 There were no changes in pulse or systolic 
blood pressure noted in either treatment arm, and a small 
decrease in diastolic blood pressure was noted in the combi-
nation dosing group compared with each drug alone. There 
were no serious adverse events and no events of syncope in 
either treatment arm.32
Efficacy
Three large-scale, placebo-controlled, Phase III studies 
evaluated the efficacy and safety of mirabegron compared 
with placebo using doses of 25 mg, 50 mg, and 100 mg; one 
study utilized the 25 mg and 50 mg doses (NCT00912964) 
whereas the others evaluated the 50 mg and 100 mg doses. 
Study sites were located internationally (NCT00689104 
[Europe and Australia],39 NCT00912964 [Europe, the US, 
Canada],40 and NCT00662909 [the US and Canada]).41 Two 
of the studies (NCT00689104 and NCT00912964) included 
tolterodine extended-release 4 mg once daily as an active 
comparator. Inclusion criteria were identical for all three 
trials, consisting of both men and women $18 years of age 
(the majority female) who were required to have an average 
micturition frequency of at least eight episodes per 24 hours 
and at least three episodes of urgency, with or without 
incontinence, during a 3-day period. The studies excluded 
patients with stress incontinence or mixed incontinence with 
predominant stress incontinence and a .3,000 mL daily urine 
volume. The study design consisted of a 2-week, single-blind, 
placebo run-in period followed by a 12-week treatment period 
with visits scheduled at 4, 8, and 12 weeks. Efficacy was 
assessed using 3-day voiding diaries prior to each clinic visit. 
Coprimary efficacy endpoints were mean change in number 
of incontinence episodes and micturitions per 24 hours from 
baseline to final visit. Secondary endpoints included changes 
in volume voided per micturition, mean number of urgency 
and urge incontinence episodes, and various quality of life 
scores, ie, an OAB questionnaire, treatment satisfaction 
visual analog scale (TS-VAS), and patient perception of 
bladder condition (Table 1). In the Nitti et al study, significant 
improvements in all key secondary endpoints were observed 
for both mirabegron doses versus placebo.41 Khullar et al also 
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Table 1 Multi-trial comparisons of coprimary efficacy endpoints and quality of life measures
Nitti et al41 Khullar et al39 Van Kerrebroeck et al40
PBO Mirabegron 
50 mg
Mirabegron 
100 mg
PBO Mirabegron 
50 mg
Mirabegron 
100 mg
PBO Mirabegron 
25 mg
Mirabegron 
50 mg
Coprimary efficacy endpoints
incontinence episodes per 24 hours (FAS-i)
n 325 312 296 291 293 281 262 254 257
Baseline 
(mean)
3 2.8 2.7 2.67 2.83 2.89 2.43§ 2.65§ 2.51§
Change from 
baseline
-1.13 -1.47# -1.63# -1.17 -1.57 -1.46 -0.96 -1.36 -1.38
Difference 
from PBO
NA -0.34 -0.5 NA -0.41 -0.29 NA -0.40 -0.42
95% Ci NA (-0.66, -0.3)§ NR NA (-0.72, -0.09) (-0.61, 0.03) NA (-0.74, -0.06)§ (-0.76, 
-0.08)§
P value NA 0.026§ NR NA 0.003# 0.010# NA 0.005# 0.001#
Micturitions per 24 hours (FAS)
n 433 425 412 480 473 478 415 410 426
Baseline 
(mean)
11.5 11.8 11.7 11.71 11.65 11.51 11.48§ 11.68§ 11.66§
Change from 
baseline
-1.05 -1.66# -1.75# -1.34 -1.93 -1.77 -1.18 -1.65 -1.60
Difference 
from PBO
NA -0.61 -0.70 NA -0.60 -0.44 NA -0.47 -0.42
95% Ci NA NR NR NA (-0.90, -0.29) (-0.74, -0.13) NA (-0.82, -0.13)§ (-0.76, 
-0.08)§
P value NA NR NR NA ,0.001# 0.005# NA 0.007# 0.015#
Quality of life measures
Treatment satisfaction visual analog scale (TS-vAS)¶
Mean (Se) 0.70 
(0.16)
1.55 (0.16)♮ 2.09 (0.16)♮ 1.89 
(0.146)
2.55 ( 0.149)♮ 2.66 (0.146)♮ 1.05 1.54♮ 1.88♮
Mean diff 
from PBO 
(Se)
NR NR NR NA 0.66 (0.208) 0.77 (0.207) NR NR NR
95% Ci (0.4, 1.0) (1.2, 1.9) (1.8, 2.4) NA (0.25–1.07) (0.36–1.17) (0.75,1.35) (1.24, 1.84) (1.58, 2.18)
P value NA , 0.05 ,0.05 NA 0.001 ,0.001 NA 0.024 ,0.001
Overactive bladder questionnaire (OAB-q) Symptom Bother Score¶
Mean (Se) -10.8 
(0.97)
-17.0 (0.98)♮ -20.2 (0.99)♮ -14.9 
(0.84)
-19.6 (0.85)♮ -19.9 (0.84)♮ -16 -17.9♮ -18.8♮
Mean diff 
from PBO 
(Se)
NR NR NR NA -4.17 (1.19) -5.0 (1.19) NR NR NR
95% Ci (-12.7, 
-8.9)
(-18.9, -15.1) (-22.1, -18.2) NA (-7.1 to -2.4) (-7.3 to -2.6) (-17.8, -14.3) (-19.6, -16.1)  (-20.5,-
17.1)
P-value NA , 0.05 , 0.05 NA , 0.001 , 0.001 NA 0.15 0.028
Patient perception of bladder condition (PPBC)¶
Mean (Se) -0.5 (0.1)-0.7 (0.1)♮ -0.8 (0.1)♮ -0.8 (0.05)-1.0 (0.06)♮ -1.1 (0.05)♮ -0.7 -0.8♮ -0.7♮
Mean diff 
from PBO 
(Se)
NR NR NR NA -0.2 (0.08) -0.2 (0.08) NR NR NR
95% Ci (-0.6, 
-0.4)
(-0.8, -0.6) (-0.9, 0.7) NA (-0.3 to -0.0) (-0.4 to -0.01) (-0.8, -0.6)  (-0.9, -0,6)  (-0.8, -0.6)
P-value NA ,0.05 ,0.05 NA 0.045 0.001 NA 0.49 0.64
Notes: Data are adjusted mean changes from baseline generated from the analysis of covariance (ANCOvA) model with treatment group, sex, and geographic 
region as fixed factors, and baseline as a covariate. Data are for the FAS (full analysis set), except for incontinence outcomes, which are for the FAS-I. P-values 
are pairwise comparisons versus placebo in the ANCOVA model or stratified rank ANCOVA model for incontinence outcomes. Data from Astellas Prescribing 
information;38 Nitti et al;41 Khullar et al;39 and van Kerrebroeck et al.40 §data from Andersson.13 #P , 0.05 with multiplicity adjustment. ♮P , 0.05 without multiplicity 
adjustment. ¶for TS-vAS an increase in value indicates improvement. For OAB-q Symptom Bother Score and PPBC a decrease in value indicates improvement. 
Abbreviations: PBO, placebo; CI, confidence interval; FAS-I, full analysis set incontinence; FAS, full analysis set; NR, not reported; NA, not applicable; SE, standard 
error; TS-vAS, treatment satisfaction visual analog scale; OAB-q, overactive bladder questionnaire; PPBC, patient perception of bladder condition.
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demonstrated statistically significant improvements in key 
secondary efficacy endpoints.39
A pooled analysis evaluating the efficacy and safety 
of mirabegron using these three Phase III studies was 
recently published.42 The efficacy analysis was only per-
formed on 50 mg (all three studies) and 100 mg mirabegron 
(NCT0066290941 and NCT0068910439) groups. Coprimary 
and secondary efficacy endpoints were the same as previously 
mentioned. Secondary endpoints also included the proportion 
of “responders”, divided into complete continence, $50% 
decrease from baseline in mean number of incontinence 
episodes/24 hours, and up to eight micturitions/24 hours at 
final visit (last category determined by post hoc analysis). 
A statistically significant improvement was noted in mean 
change from baseline to the final visit with regard to both 
coprimary endpoints for both 50 mg and 100 mg mirabegron 
when compared with placebo (P,0.05 for all comparisons). 
Statistically significant improvements were also seen in 
both mirabegron groups when compared with placebo for 
all secondary endpoints, including change from baseline to 
the final visit in mean volume voided/micturition, change 
from baseline to week 4 in mean number of incontinence 
episodes/24 hours, change from baseline to week 4 in mean 
number of micturitions/24 hours, mean level of urgency, 
mean number of urgency incontinence episodes/24 hours, 
mean number of urgency episodes (grade 3/4), change 
from baseline to final visit in mean number of nocturia epi-
sodes/24 hours, and change from baseline to final visit in 
TS-VAS scores. Responder analysis showed that mirabegron 
50 mg and 100 mg were 1.32 (95% CI 1.08–1.61) and 1.58 
(95% CI 1.25–2.00) times more likely to achieve complete 
continence at the final visit compared with placebo (P,0.05). 
With regards to achieving a $50% reduction from baseline to 
final visit in mean number of incontinence episodes/24 hours, 
50 mg and 100 mg mirabegron were 1.54 (95% CI 1.26–1.89) 
and 1.64 (95% CI 1.29–2.07) times more likely to achieve this 
than placebo, respectively, which was statistically signficant 
(P,0.05). Similar odds ratios also existed for both dose 
groups with regard to reduction in micturitions at the final 
visit to #8/24 hours (P,0.05). Further statistical analysis 
was performed for two patient groups, ie, those who discon-
tinued previous antimuscarinic medications (the majority due 
to insufficient effect) and those who were treatment-naïve. In 
the patients who had previously used antimuscarinics, both 
mirabegron 50 mg and 100 mg showed a significant adjusted 
mean change (95% CI) in mean number of incontinence 
episodes/24 hours from baseline to final visit, but only the 
50 mg group showed a statistically significant difference 
compared with placebo, ie, -1.49 (-1.66, -1.32) and -0.92 
(-1.09, -0.75),  respectively. Analysis of the other coprimary 
endpoint, ie, mean number of micturitions/24 hours from 
baseline to final visit, in patients who previously discontinued 
antimuscarinics, showed a statistically significant adjusted 
mean difference (95% CI) in both dosage groups and also 
when compared with placebo (-0.93 [-1.12, -0.74], -1.67 
[-1.86, -1.48], and -1.61 [-1.85, -1.37] for placebo, mira-
begron 50 mg, and mirabegron 100 mg, respectively).
A randomized, double-blind, active-controlled, Phase III 
study was performed to assess the 12-month safety and 
efficacy of mirabegron 50 mg and 100 mg.44 The inclusion 
criteria and study design were identical to the previous 
Phase III studies, except that the double-blind treatment 
period was extended to 12 months. Assessment of efficacy 
endpoints was done at 1, 3, 6, 9, and 12 months. Tolterodine 
extended-release 4 mg served as the active control. Improve-
ment in efficacy variables was noted in all three treatment 
groups, starting at the first visit (month 1) and maintained to 
month 12. Treatment with mirabegron 100 mg was associated 
with a numerically greater improvement in efficacy outcomes 
(mean number of incontinence episodes and micturitions per 
24 hours and mean volume voided per micturition). Treatment 
with tolterodine extended-release 4 mg also led to a reduction 
in mean number of incontinence episodes and micturitions 
per 24 hours, and the mean volume voided per micturition 
was numerically higher than both doses of mirabegron for 
mean number of incontinence episodes and micturitions per 
24 hours at 12 months. Numeric improvements were seen 
in all three treatment groups for the secondary variables, 
including the OAB questionnaire, health-related quality of 
life, patient perception of bladder condition, TS-VAS, and 
number of nocturia episodes. This study was not designed to 
demonstrate a statistically significant difference in efficacy 
between treatment groups.
Combination therapy
Although approved by the US Food and Drug Administra-
tion as monotherapy for the treatment of OAB, the unique 
mechanism of action of mirabegron supports the concept 
of combination therapy with an anticholinergic agent. 
A factorial-design, multicenter, randomized, double-blind, 
parallel-group, placebo/monotherapy-controlled Phase II 
trial was performed in men and women aged $18 years with 
OAB symptoms for at least 3 months.43 The study design 
involved a 2-week, single-blind, placebo run-in period. 
Patients with eight or more micturitions per 24 hours and 
three or more urgency episodes per 72 hours (with or without 
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incontinence) on a 3-day micturition diary were randomized 
to one of 12 treatment arms with once-daily treatment for 
12 weeks (Table 1).
Mirabegron 25 mg or 50 mg combination therapy with 
solifenacin 5 mg or 10 mg demonstrated significantly greater 
efficacy than solifenacin 5 mg alone on change from baseline 
to end of treatment in mean volume voided per micturition 
(all dose combinations) and micturition frequency (10 mg 
+25 mg, 5 mg +50 mg, and 10 mg +50 mg). Statistically 
significant differences versus placebo were seen on treatment 
with the solifenacin/mirabegron combinations at doses of 
5 mg +50 mg, 10 mg +25 mg, and 10 mg +50 mg.
A post hoc mixed-effect Poisson regression model 
demonstrated a statistically significant decrease in the mean 
number of incontinence episodes per 24 hours at the end of 
treatment versus both placebo and solifenacin 5 mg for the 
solifenacin/mirabegron combination at doses of 5 +25 mg 
and 5 mg +50 mg. There was no significant increase in 
adverse events with the combination treatment compared 
with mirabegron or solifenacin monotherapy.43
Safety and tolerability
General safety
A randomized, double-blind, active-controlled, Phase III study 
was performed to assess the 12-month safety and efficacy of 
mirabegron 50 mg and 100 mg.44 The primary safety variable 
was the incidence and severity of treatment-emergent adverse 
events. At selected investigational sites, a subset of patients 
underwent ambulatory blood pressure monitoring, in which 
blood pressure and heart rate were assessed every 15 minutes 
during a 24-hour period at baseline and at 6 months and 
12 months. Treatment-emergent adverse events were reported 
in 59.7% and 61.3% of patients receiving mirabegron 50 mg 
and 100 mg, respectively. Most of the treatment-emergent 
adverse events were mild or moderate in severity. The most 
frequent were hypertension (9.2% and 9.8%), dry mouth 
(2.8% and 2.3%), constipation (2.8% and 3.0%), and head-
ache (4.1% and 3.2%) for mirabegron 50 mg and 100 mg, 
respectively. Discontinuation due to adverse events occurred 
in 6.4% and 5.9%, respectively. Urinary retention occurred 
in one patient on mirabegron 50 mg and one patient on 
mirabegron 100 mg. There was no acute urinary retention in 
the mirabegron 50 mg group. Acute urinary retention requir-
ing catheterization occurred in one patient on mirabegron 
100 mg. The incidence of cardiac arrhythmias was 3.9% in 
the mirabegron 50 mg group and 4.1% in the mirabegron 
100 mg group. Adjusted mean changes from baseline to final 
visit for systolic blood pressure in the mirabegron 50 mg and 
100 mg groups were 0.2 mmHg and 0.4 mmHg for morn-
ing measurements and -0.3 and 0.1 mmHg for afternoon 
measurements. Adjusted mean changes for diastolic blood 
pressure were -0.3 and 0.4 mmHg for morning measure-
ments and -0.0 and 0.1 mmHg for afternoon measurements. 
The mean change in pulse rate from baseline was 1.6 and 
1.5 beats per minute for 100 mg and 50 mg of mirabegron, 
respectively. No consistent trends in electrocardiographic 
changes were noted.
A pooled safety analysis of the three randomized, double-
blind, placebo-controlled Phase III studies demonstrated 
the overall incidence of treatment-emergent adverse events 
to be similar across treatment groups, with no evidence 
of a dose-response across the groups for overall rates of 
treatment-emergent adverse events (placebo [47.7%], mira-
begron 25 mg [48.6%], mirabegron 50 mg [47.1%], and 
Table 2 Reported treatment-related adverse events of mirabegron $2%
Adverse events Khullar et al39,§ Nitti et al41,§ Van Kerrebroeck et al40,#
Placebo Mirabegron 
50 mg
Mirabegron 
100 mg
Placebo Mirabegron 
50 mg
Mirabegron 
100 mg
Placebo Mirabegron 
25 mg
Mirabegron 
50 mg
Hypertension 7.7% 5.9% 5.4% 6.6% 6.1% 4.9% 8.5% 11.3% 10.7%
Nasopharyngitis 1.6% 2.8% 2.8% 2.9% 3.4% 2.5% 3.2% 3.5% 5.7%
Dry mouth 2.6% 2.8% 2.8% 1.5% 0.5% 2.1% * * *
Headache 2.8% 3.7% 1.8% 2.0% 3.2% 3.0% 4.4% 2.1% 2.7%
Influenza 1.6% 2.2% 2.0% NR NR NR NR NR NR
Sinusitis NR NR NR 2.2% 2.0% 2.1% NR NR NR
Upper respiratory 
tract infection
* * * 2.5% 2.7% 2.1% 1.3% 2.1% 1.6%
Urinary tract 
infection
* * * 1.8% 2.7% 3.7% 3.3% 4.2% 4.8%
Diarrhea NR NR NR 1.3% 2.7% 2.1% NR NR NR
Notes: *Reported but ,2% for treatment groups; §includes events reported from first dose of double-blind treatment until 30 days after the last dose of double-blind study 
drug; #includes events reported from first dose of double-blind treatment until 14 days after the last dose of double-blind study drug.
Abbreviation: NR, not reported. 
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 mirabegron 100 mg [43.3%]).42 The most common drug-
related treatment-emergent adverse events in the mirabegron 
groups were hypertension and headache, which were of 
similar incidence to that with placebo and tolterodine, except 
for dry mouth, which was at the placebo level for mirabegron 
(Table 2). The proportion of patients discontinuing the study 
drug because of treatment-emergent adverse events was low 
and similar across the groups (placebo [2.1%], mirabegron 
25 mg [1.6%], mirabegron 50 mg [2.1%], and mirabegron 
100 mg [2.8%]). The adjusted mean difference versus pla-
cebo for change from baseline to final visit in systolic and 
diastolic blood pressure (morning and afternoon measure-
ments) was minimal and comparable across the mirabegron 
groups. The adjusted mean difference versus placebo for 
change from baseline to final visit in pulse rate (morning and 
afternoon measurements) demonstrated a dose-dependent 
increase from 0.6 to 2.3 beats per minute in the mirabegron 
groups. Tachycardia, based on treatment-emergent adverse 
events and/or observations of pulse rate .100 beats per 
minute captured by patient diary, was less than 5% in each 
mirabegron treatment group and comparable with placebo. 
Electrocardiographic studies did not demonstrate any overt 
trends in central tendency or categoric outliers for QTc 
interval assessment across treatment groups. Changes in 
laboratory values were small and comparable across the 
treatment groups. The incidence of urinary retention was 
infrequent in the studies and less in the mirabegron-treated 
patients than in placebo-treated patients. The mean change 
in post-void residual from baseline to final visit was unre-
markable, and the proportion of patients with a change in 
post-void residual of .150 mL from baseline was lower in 
the mirabegron group compared with the placebo group.
Postmarketing, there have been reports of urinary reten-
tion with mirabegron, although Chapple et al45 reported 
no episodes of acute urinary retention in the BLOSSOM 
trial, nor were there any reported by Chapple et al in the 
DRAGON trial.46
Ocular safety
Muscarinic receptors are present in the eye, where they medi-
ate the contractility response and are involved in the autonomic 
control of the iris sphincter.47 Muscarinic antagonists with an 
affinity for the M3 receptor can have ocular effects, such as 
mydriasis, loss of accommodation, and narrowing of the 
anterior chamber. The antimuscarinic agents approved for the 
treatment of OAB are contraindicated in patients with uncon-
trolled narrow angle glaucoma, and caution is recommended 
regarding their use in treated narrow angle glaucoma. The role 
of beta-3 adrenoceptors in the eye is not fully understood. 
In vitro studies have demonstrated that the beta-adrenergic 
relaxation response in the bovine iris sphincter appears to be 
mediated by a mixed population of beta-adrenergic receptors, 
including beta-3 adrenoceptors. Additional animal studies 
have demonstrated the presence of beta-3 adrenoceptors in 
mouse conjunctival epithelial cells48,49 and choroidal and reti-
nal endothelial cells,50,51 and their involvement in the control 
of retinal vascular tone in rats.52
An 8-week, randomized, double-masked, placebo-con-
trolled study was performed to assess the ocular safety of 
mirabegron in healthy volunteers.53 Individuals were random-
ized 1:1 to a supratherapeutic dose of oral mirabegron 100 mg 
or placebo once daily for 56 days. Intraocular pressure was 
measured at screening, baseline, day 10, and day 56 (end of 
treatment) using Goldmann applanation tonometry. Visual 
acuity and biomicroscopy were also evaluated. The primary 
endpoint was mean change from baseline in intraocular pres-
sure at 56 days or end of treatment with mirabegron versus 
placebo. Secondary outcome variables included change from 
baseline to day 10 in intraocular pressure, and increases in 
intraocular pressure of .6 mmHg and .10 mmHg in either 
eye from baseline to day 10 and day 56. For the primary end-
point, mirabegron was noninferior to placebo, based on the 
prespecified limit of 1.5 mmHg. No statistically significant 
treatment effects on intraocular pressure were seen at day 10. 
Changes in visual acuity and biomicroscopy were not sugges-
tive of a mirabegron effect. Further, no treatment-emergent 
adverse event of glaucoma was reported.
Cardiovascular safety
International Conference on Harmonisation E14 guidance54 
requires a thorough QT/QTc (heart rate-corrected QT 
 interval) study for all new drugs, including at supraphysi-
ologic doses. Animal studies with mirabegron have demon-
strated no inhibitory effect towards ion channels (including 
ether-à-go-go-related gene), action potential duration, or 
transmural repolarization.34 Since mirabegron increases 
heart rate at supratherapeutic doses (.50 mg), the QTc 
study used individual subject-specific correction formula 
(QTcIs55 with adaptation for heart rate hysteresis)56 instead 
of the commonly used Fridericia’s (QTcF) correction because 
Fridericia’s correction does not provide accurate QTc values 
in the presence of drug-induced changes in heart rate.57 Three 
hundred and fifty-two subjects received at least one dose of 
study medication, and pharmacokinetic and pharmacody-
namic analyses were performed on 333 and 317 subjects, 
respectively.34 An equal number of males and females were 
enrolled in each group. The study design was a four-arm, 
parallel, two-way crossover study, which was double-blind, 
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as well as placebo-controlled and active (moxifloxacin)-
controlled. Two baseline electrocardiograms were obtained, 
and patients were then randomized to one of eight treatment 
sequences of placebo crossover with once-daily (10 days) 
50 mg, 100 mg, or 200 mg mirabegron or a single 400 mg 
moxifloxacin dose on day 10. During each period, continuous 
electrocardiograms were recorded at two baselines and on the 
last drug administration day. The primary variable was the 
time-matched baseline-adjusted QTcI difference (∆∆QTcI) 
between individual mirabegron doses and placebo by sex. The 
mean ∆∆QTcI increased at higher mirabegron doses, with a 
greater effect in females than in males. In both genders, at the 
50 mg therapeutic dose, the mean ∆∆QTcI was below 5 msec 
at all time points, and the upper bound of the one-sided 95% 
CI did not exceed 10 msec. However, at the supratherapeutic 
100 mg dose, the mean ∆∆ QTcI was above 5 msec at various 
time points for women only, and in both genders, the upper 
bound of the one-sided 95% CI did not exceed 10 msec. The 
supratherapeutic 200 mg dose did not exceed 10 msec in men, 
but did exceed 10 msec in women at various time points. Thus, 
at the therapeutic dose of 50 mg and the supratherapeutic 
dose of 100 mg, according to the International Conference 
on Harmonisation E14 criteria, mirabegron did not pro-
long the QTcI interval.34 In this study, the maximum mean 
increase in supine systolic/diastolic blood pressure at the 
maximum recommended dose of 50 mg was approximately 
4.0/1.6 mmHg greater than on placebo. The 24-hour average 
increase in systolic blood pressure compared with placebo 
was 3.0 mmHg, 5.5 mmHg, and 9.7 mmHg at mirabegron 
doses of 50 mg, 100 mg, and 200 mg, respectively. Increases 
in diastolic blood pressure were dose-dependent, but were 
smaller than for systolic blood pressure.
Phase I studies demonstrated a mirabegron-related, 
dose-responsive increase in blood pressure of approxi-
mately 3–4 mmHg at C
max
. In Phase III studies, mirabegron-
related increases in systolic and diastolic blood pressure 
were only about 1 mmHg. A similar discordance was seen 
between the increases in heart rate in Phase I and Phase 
III studies, and the reasons for these different results are 
not clear.19
Malignancy
The Phase II studies reported an increased incidence of a 
variety of neoplasms in the mirabegron 100 mg group com-
pared with the placebo group. This increased incidence was 
not seen with patients receiving mirabegron 50 mg, and it 
is unclear if there is a true mirabegron-related effect.19,32 In 
the long-term European Union/North American trials, the 
overall incidence of neoplasms was 0.9% in patients treated 
with mirabegron 100 mg and 0% in those treated with mira-
begron 50 mg.32
Tolerability
The more common side effects of mirabegron differ 
from those of the antimuscarinics, reflecting the different 
mechanisms of action of these agents. The more com-
mon side effects, ie, those occurring in .2% of patients, 
in the Phase III registration trials are shown in Table 2, 
with notably higher rates of urinary tract infection and 
nasopharyngitis in the mirabegron groups compared with 
placebo.39–41 The incidence of dry mouth was comparable 
with that on placebo and less than that in the tolterodine 
group (data not shown).
Patient-centered factors
With regard to health-related quality of life outcomes, 
a pooled analysis of the Phase III studies demonstrated 
that mirabegron 50 mg and 100 mg were associated with 
a statistically significant improvement in TS-VAS score 
compared with placebo (P,0.05) at the final visit.42 The 
TS-VAS is a quantitative instrument assessing subjective 
improvement in patients with OAB. A score of 10 on the TS-
VAS indicates complete satisfaction, whereas a positive 
change from baseline indicates improvement. The adjusted 
mean (95% CI) changes from baseline to the final visit were 
1.25 (1.08–1.42), 2.01 (1.84–2.19), and 2.33 (2.11–2.55) 
for the placebo,  mirabegron 50 mg, and 100 mg groups, 
 respectively (Table 1).42 Statistically significant improve-
ments in the OAB questionnaire and patient perception of 
bladder condition were also noted for mirabegron 50 mg and 
100 mg in all three Phase III trials, except for the trial reported 
by Van Kerrebroeck et al,40 which did not show a statistically 
significant change from baseline in patient perception of 
bladder condition for mirabegron 50 mg (Table 1).
Conclusion
The increasing prevalence of OAB combined with low long-
term patient compliance with antimuscarinic agents indi-
cates a need for alternative treatment options. Mirabegron 
represents such an alternative by selectively targeting beta-3 
adrenoceptors within the bladder to promote filling during 
the storage phase without inhibiting contractions during 
micturition. Pharmacokinetic studies do not preclude food 
consumption while taking mirabegron, although the dosage 
should be adjusted for severe renal or hepatic impairment. 
Inhibition of CYP enzymes has been shown, so care should 
be taken when administering mirabegron with digoxin or 
metoprolol. Recently completed Phase III studies show 
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significant improvement in both the number of incontinence 
episodes and the mean number of micturitions per 24 hours, 
as well as in validated disease specific patient questionnaires 
over placebo. Few studies have been performed with active 
controls, although the current data suggest long-term effects 
comparable with those of the antimuscarinic agents. The drug 
is well tolerated with minor adverse effects, most notably a 
lower rate of dry mouth compared with the antimuscarinics, 
making mirabegron a reasonable treatment option in patients 
unable to tolerate first-line medical therapy.
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